Medifast director Scott Schlackman acquires 5,000 shares in two tranches as stock trades well below its 52-week high amid unprofitable fundamentals.
Director Scott Schlackman purchased 5,000 shares over two trading days in early May at prices near current levels, adding to two prior open-market purchases he made in 2023. The stock is currently trading roughly 18% below its 52-week high and has risen modestly over the past three months, yet the company remains unprofitable despite significant recent revenue expansion. Schlackman's prior purchases in 2023 are too recent to evaluate their timing outcomes, but this repeat buying at depressed valuation levels adds conviction to his earlier accumulation. The pattern of a director buying into weakness while the company operates at a loss suggests either confidence in an inflection point or positioning for longer-term recovery; however, without recent earnings results or visibility into near-term profitability, this trade enters a fundamentally challenged environment.